

## COMBATting FUTURE BIOLOGICAL THREATS – HOST-DIRECTED INTERVENTIONS TO EMERGING THREATS FOR RAPID RESPONSE

### Scrna-seq Analysis Of Melioidosis Patient Outcomes

**Bin Hu** Los Alamos National Laboratory **Martha Dix** Bioscience Division, Los Alamos National Laboratory **Kaitlyn Li** Bioscience Division, Los Alamos National Laboratory **Sineenart Sengyee** Department of Microbiology and Immunology, University of Nevada, Reno School of Medicine **Narisara Chantratita** Department of Microbiology and Immunology and Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University **Mary Burtnick** Department of Microbiology and Immunology, University of Nevada. Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand **Paul Brett** Department of Microbiology and Immunology, University of Nevada, Reno School of Medicine. Department of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

Single cell transcriptomic (scRNA) analysis is a powerful tool to analyze immune response, among other applications. However, the analysis of the single cell transcriptomic data is not standardized and can be subjective. We compared the performance of different tools and parameter settings using a 10X data set collected from human peripheral blood mononuclear cells (PBMC). Peripheral blood mononuclear cells were collected from healthy donors and donors diagnosed with *Burkholderia pseudomallei* by collaborators. This study examines human gene expression and bacterial genomes in parallel for insights on patient outcome while building a novel analysis pipeline. Data was analyzed using Kallisto-Bustools, Cell Ranger, Scanpy, SCVI-tools, leiden clustering, py-DeSeq2, and PhaME. Our analysis revealed the importance of removing different types of low-quality data and the challenges of standardizing tool parameters. The results, combined with further research, can help to better understand which methods are the most effective for scRNA-seq analysis. Our results suggest scRNA may be a promising tool to develop biomarkers for predicting clinical outcome.

This work was supported by the Defense Threat Reduction Agency under the Rapid Assessment of Platform Technologies to Expedite Response (RAPTER) program (award no. HDTRA1242031). The authors would like to thank Dr. Traci Pals and Dr. Bob Webb for their support of this work.